我们的肿瘤新药初显成效？可以对比一下最近超著名的药物Opdivo 当时的动物试验数据： MC38 model in C57BL/6 mice (MDX-1106-023R 930046542, MDX-1106-032R 930046566) MC38 cells are colon adenocarcinoma cells derived from C57BL/6 mice that express PD-L1 in vivo, although in vitro expression of PD-L1 is very low. Two in vivo studies with MC38 tumours were conducted in mice. In both Assessment report EMA/CHMP/76688/2015 Page 30/130 studies mice were transplanted with an unstaged MC38 tumour (subcutaneous implantation of 2 million cells) and treated with control IgG or anti-PD-1 antibody 4H2 (nivolumab murine surrogate) at 10 mg/kg IP. In the first study each animal received the first antibody or control dose the same day of the tumour implantation, and additional doses on days 3 and 6 post-implantation. At day 21, 83% tumour growth inhibition was observed, with 30% of mice tumour-free at the study endpoint. In the other study, treatment with control IgG or anti-PD-1 antibody 4H2 was conducted on days 7 post-tumour implantation and again on days 10 and 13, resulting in a mean tumour growth inhibition of 62% at day 13 and a median growth inhibition of 76% by day 20. Opdivo 使用MC38肿瘤，我们使用LLC肿瘤 Opdivo 用2*106接种 我们用5*106接种 Opdivo 13天的抑癌率是62% 我们10天的抑癌率是57% Opdivo 21天的抑癌率是83%，我们没有数据 综合比较，就初步的动物试验，我们的试验数据并不比Opdivo 差。查看更多
第1天
关注盖德视界
添加小助手
